WELLO2
18.5.2020 07:02:06 CEST | Business Wire | Press release
Training with a counter pressure steam breathing device has the potential to improve voice quality, as revealed in a recent pilot study in Finland. A report on the study was published in Journal of Voice, a peer-reviewed publication regarded as the world's premiere journal for voice medicine and research.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200517005004/en/
The protocol of another study, now investigating benefits of using WellO2, a unique counter pressure steam breathing device, with patients with chronic obstructive pulmonary symptoms, has been approved by the ethical committee of the University of Tampere. Both studies focus on the effects of the combination of the inspiratory and expiratory muscle training with warm steam.
Voice professionals have found help
Even before the Finnish study came out, various renown voice professionals have been using WellO2 to help with their voice problems. Among the artists is Uriah Heep’s lead singer Bernie Shaw , who has warmly endorsed WellO2 (see link, below).
The aim of the Finnish pilot study was to determine the efficacy of the 4-week breathing exercise intervention on participants with voice symptoms. Six non-smoking women, mean age 49, experiencing voice symptoms made respiratory muscle exercises for a month with counter pressure on both inspiration and expiration and with warm steam. Speech samples were acoustically measured and perceptually analyzed using the GRBAS, the grade, roughness, breathiness, asthenia and strain scale. Afterwards, perceived voice symptoms and self-reported effort in breathing and phonation were analyzed.
Participants: Breathing was significantly less effortful
The total score of the Acoustic Voice Quality Index (AVQI) and some of its subcomponents, namely shimmer and harmonic-to-noise ratio, and the perceptually evaluated grade, roughness, and strain indicated significantly improved voice quality. However, neither the nature or frequency of the experienced voice symptoms nor the perceived phonatory effort changed as the function of intervention. According to the participants, their breathing was significantly less effortful after the intervention, although no significant changes were observed in the objective respiratory measurements with a spirometer.
According to the study, training with the WellO2 device has the potential to improve voice quality. However, the effects of using WellO2 need to be confirmed by further studies with a larger number of participants, the pilot study concluded.
New studies with WellO2 and chronic obstructive pulmonary symptoms
The ethical committee of the University of Tampere recently gave a positive statement for the clinical study of WellO2 with patients with chronic obstructive pulmonary symptoms. The team is testing the effect of WellO2 device for the respiratory muscle exercises that provides counter pressure. There are several hundreds of referred studies on steam inhalation and counter pressure breathing. None have found any severe side effects for using such devices.
Patented WellO2 counter pressure steam breathing device was developed by Hapella Oy, Finland. The device has been available since 2016 as a non-medical device. Over 35 000 devices have been sold in Finland, alone. It is sold both in pharmacies and other stores, like electric commodity store chain of Elgiganten in Sweden and Elkjøp in Norway. Wello2 is available on e-commerce, also at various Amazon e-stores, e.g. in Italy and Germany.
Medical references & links:
https://wello2.com/blogs/news/wello2-counter-pressure-steam-breathing-helps-with-voice-symptoms
View source version on businesswire.com: https://www.businesswire.com/news/home/20200517005004/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
REPLY: The Board of Directors Approved the Draft Financial Statements for the Year 202512.3.2026 15:38:00 CET | Press release
All economic indicators are positive.Consolidated turnover of €2,483.6 million (€2,300.5 million in 2024);EBITDA at €467.6 million (€410.6 million in 2024);EBIT at €391.7 million (€330.4 million in 2024)Group net profit at €250.9 million (€211.1 million in 2024)Approval of the proposed dividend distribution of €1.35 per share. Today the Board of Directors of Reply S.p.A. [MTA, STAR: REY] approved the draft financial statement for the year 2025, which will be submitted for approval to the Shareholders’ Meeting to be held in first call in Turin on 23 April 2026. The Reply Group closed 2025 with a consolidated turnover of €2,483.6 million, an increase of 8.0% compared to €2,300.5 million in 2024. All indicators are positive for the period. Consolidated EBITDA was €467.6 million, an increase of 13.9% compared to €410.6 million at December 2024. EBIT, from January to December, was at €391.7 million, which is an increase of 18.5% compared to €330.4 million at December 2024. The Group net pro
LZE GmbH Introduces Fraunhofer’s RFicient® Technology to the Market12.3.2026 14:51:00 CET | Press release
LZE GmbH is expanding its technology transfer portfolio and making the RFicient® ultra-low-power wake-up receiver technology from the Fraunhofer Institute for Integrated Circuits IIS available for the first time as a standard chip for close-to-production industrial applications. The solution enables energy-efficient IoT designs that remain continuously reachable while consuming only microamps – a key step for long-lasting, low-maintenance IoT products. LZE GmbH drives technology transfer to market: standard chip availability for close-to-production applications As a bridge between research and industry, LZE GmbH is making it easier for companies to access innovative technologies and helping them to quickly and reliably transform new developments into market-ready solutions. With RFicient®-IC (FH101RF), LZE is providing another high-tech product that comes directly from Fraunhofer research and can now be ordered in volume and integrated into close-to-production product development for t
Owkin Creates New Spin out Waiv, Formerly Owkin Dx, With $33M Financing12.3.2026 14:30:00 CET | Press release
Investment lead by OTB Ventures and Alpha Intelligence CapitalWaiv develops AI-powered precision testing to better identify and stratify patients in the clinic and in clinical trials, transforming patient careWaiv extends Owkin’s strategy of real-world validation for its AI Owkin, the AI company on a mission to solve the complexity of biology, today announced the spin out of Waiv, formerly known as Owkin Dx. The move follows significant investor interest and positions Waiv to bring AI-powered precision testing for better identification of patients in the clinic and in clinical trials, to transform patient care. This follows on from the successful launch of Bioptimus, an Owkin incubated company, in February 2024. Waiv translates AI innovation into real-world clinical impact, developing tests that predict biomarkers and patient outcomes, including RlapsRisk BC for prognostic risk profiling. With multiple tests already in use in clinical settings, its deployment platform Destra, and colla
RQM+ Launches SMART Solutions Life Cycle Partnership Model12.3.2026 14:30:00 CET | Press release
Helps MedTech Companies Navigate MDR, IVDR, and AI-Enabled Device Development RQM+, a leading MedTech CRO offering regulatory consulting, clinical trial, laboratory, and reimbursement services, today announced the launch of SMART Solutions, a life cycle partnership model designed to help medical device and diagnostics companies manage growing regulatory and development complexity. SMART Solutions introduces a strategy-led operating framework that unifies regulatory, quality, clinical, reimbursement, and laboratory expertise to support MedTech companies across the entire product life cycle to help reduce risk from early development through post-market. “MedTech companies are navigating unprecedented complexity as regulatory expectations evolve, product innovation accelerates, and post-market expectations are expanding,” said John Potthoff, Ph.D., chief executive officer of RQM+. “SMART Solutions moves beyond traditional consulting by providing an integrated life cycle partnership that h
Cryptio Raises $45m Series B as Digital Assets Move Into Regulated Financial Markets12.3.2026 14:06:00 CET | Press release
The system of record for tokenized finance – ERP infrastructure for institutions operating in digital assets Cryptio, a leader in financial data transformation and enterprise resource planning (ERP) applications for regulated digital assets, announced today a $45 million Series B funding round co-led by BlackFin Capital Partners and Sentinel Global, with participation from 1kx, Alven, BlueYard Capital and Ledger Cathay Capital. Banks, exchanges, asset managers, including Société Générale’s SG Forge, Circle, Gemini, and Securitize rely on Cryptio to ensure financial integrity across their digital assets businesses. Existing ERP systems fall short for digital assets Traditional ERP and accounting systems were not designed for blockchain-native assets, real-time reporting, or modern custody frameworks. As regulated financial institutions expand into stablecoins, tokenized securities and other on-chain instruments, these limitations create material operational and reporting challenges. Cry
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
